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Abstract. The development of resistance to anticancer 
drugs urges the search for different reatment modalities. 
Several investigators have reported the concomitant 
development of drug resistance and resistance to natural 
killer (NK), lymphokine-activated killer (LAK) or mono- 
cyte/macrophage c ll lysis, while others described un- 
changed or even increased susceptibility. We investigated 
this subject in the rat colon carcinoma cell line, CC531- 
PAR, which is intrinsically multidrug-resistant (MDR), 
and in three sublines derived from this parental cell line: a 
cell line with an increased MDR phenotype (CC531-COL), 
a revertant line from CC531-COL (CC531-REV), which 
demonstrates nhanced sensitivity to anticancer drugs of 
the MDR phenotype, and an independently developed cis- 
platin-resistant line (CC531-CIS). In a 4-h 51Cr-release 
assay we found no difference in susceptibility to NK cell 
lysis. No significant differences in lysability by adherent 
LAK (aLAK) cells were observed in a 4-h assay. In a 
prolonged 20-h 51Cr-release assay an enhanced sensitivity 
to aLAK-cell-mediated lysis was observed in the revertant, 
P-glycoprotein-negative cell line and in the cisplatin-re- 
sistant cell line (CC531-CIS). None of the cell lines was 
completely resistant to lysis by aLAK cells. Therefore, a
role for immunotherapy in the treatment of drug-resistant 
tumors remains arealistic option. 
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Introduction 
One of the major problems in cancer chemotherapy is the 
development of resistance todrugs. Several mechanisms of
drug resistance have been elucidated; some operate against 
a particular drug, while others affect a group of' structurally 
unrelated anticancer agents, as in multidrug resistance 
(MDR). Doxorubicin, vincristine and etoposide are ex- 
amples of drugs subjected to the MDR mechanism. Multi- 
drug-resistant cells express an efflux pump, P glycoprotein 
(Pgp), which expels anticancer drugs from the cells. Ex- 
pression of the multidrug transporter can be demonstrated 
by anti-Pgp monoclonal antibodies, or at the DNA and 
RNA level by blotting techniques [26]. Resistance to a 
specific drug may be caused by several mechanisms. For 
instance, resistance to cisplatin is related to reduced rug 
accumulation, i creased etoxification and increased DNA 
repair [2]. The development of resistance to anti-cancer 
drugs urges the search for alternative treatment modalities, 
for example immunotherapy. Adoptive immunotherapy 
using interleukin-2 (IL-2) and cytotoxic ells [lymphokine- 
activated killer (LAK) cells] has proven to be effective in 
renal cell cancer. Response rates up to 35% have been 
reported. In melanoma, responses up to 21% were found. 
Response rates in colon carcinoma were lower (13%) [32]. 
All these rumors intrinsically express the MDR phenotype 
at a high frequency [15] (W. Van de Vrie et al., in prepara- 
tion). 
Before immunotherapy can be used as an alternative 
treatment after failure of chemotherapy, it is important to 
know whether there might be a correlation between drug 
resistance and sensitivity or resistance to immunotherapy. 
Reports in the literature have yielded conflicting data about 
a possible correlation between drug resistance, specially 
MDR, and resistance to natural killer (NK) and LAK cell 
lysis [33, 34]. We investigated this subject in four cell lines 
of a rat colon carcinoma with different mechanisms and 
levels of drug resistance. In our model drug resistance was 
not associated with changes in sensitivity to NK-cell-medi- 
ated lysis. Only minor alterations in sensitivity to IL-2/ad- 
herent LAK (aLAK) cell lysis were observed. 
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Materials and methods 
Animals. Male rats of the inbred WAG/RIJ (RT1 u) strain were obtained 
from Harlan-CPB (Austerlitz, The Netherlands). Animals were bred 
under specific-pathogen-free conditions and fed standard rat chow (Hope 
Farms, Woerden, The Netherlands) and water ad libitum. In the experi- 
ments, rats of 12-18 weeks old, weighing 220-280 g, were used. 
Ceil lines. CC531 is a rat colon adenocarcinoma, which was induced 
chemically in the WAG rat with 1,2-dimethylhydrazine. Themoderately 
differentiated tumor is weakly immunogenic, asdetermined by the meth- 
od described by Prehn and Main [27], and transplantable in syngeneic 
rats [20]. Following subcutaneous implantation and subsequent resec- 
tion, the tumor metastasizes to the lungs. In vivo the tumor is resistant to 
most anticancer drugs and only at the maximal tolerable dose were 
significant growth-retarding effects observed [ 19] (unpublished observa- 
tions). Cisplatin was reported to be one of the most effective drugs 
against CC531 [19]. Moderate sensitivity to immunotherapeutic agents 
like interferon "/and tumor necrosis factor c~ in vitro and in vivo has been 
shown in previous tudies [8, 20, 21, 36]. In vitro CC531, the parental 
cell line (CC531-PAR), grows as a monolayer in Dulbecco's modified 
Eagle's medium (DMEM) supplemented with 5% heat-inactivated f tal 
calf serum (FCS), L-aspargine (50 mg/1), glutamic acid (2 mM), 100 
IU/ml penicillin and 100 gg/ml streptomycin, all obtained from Gibco 
(Paisley, UK), in a humidified atmosphere of 5% CO~J95% air at 37~ 
CC531-PAR intrinsically expresses the MDR phenotype. We recently 
reported on the reversibility of MDR in vitro and in vivo in this model 
[38]. In vitro drug resistant sublines were induced by continuous incuba- 
tion with colchicin (CC531-COL) and cisplatin (CC531-CIS). Estab- 
lished cell lines were maintained in the presence of 0.2 gM colchicin and 
0.75 gM cisplatin (cis-diaminedichloroplatinum) respectively [14]. 
Compared to the parental line, CC531-COL shows enhanced resistance 
to drugs of the MDR phenotype (colchicin 33 x,  daunorubicin 10 x ) and 
to cisplatin (5.5 x ). CC531-CIS is resistant to cisplatin (9.8 • ), while it 
has approximately the same sensitivity to other drugs as the parental line. 
From CC531-COL a revertant line (CC531-REV) was isolated that is 
more sensitive to drugs of the MDR phenotype than the parental line 
Table 1. Characteristics of the CC531 cell lines 
Characteristic CC531-PAR CC531-COL CC531-REV CC531-CIS 
RF a DNR b 1 10 0.25 0.2 
RF COL 1 33 0.6 0.94 
RF VBL 1 4.4 0.3 1.0 
RF CIS 1 5.5 4 9.8 
SR c VPL 6.6 31.6 2.0 5.0 
DNR 100 64 102 ND e 
accumulation d 
Pgp + ++ +_ ND 
expresssion f 
a RF, resistance factor. Drug sensitivity was determined with the 3-(4,5- 
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) colori- 
metric cell-growth-inhibition assay for different drugs. In the table the 
relative sensitivity of the cell lines compared to the parental line is given. 
The sensitivity of CC531-PAR is arbitrarily defined as 1 
b DNR,  daunorubicin; COL, colchicin; VBL, vinblastine; CIS, cis-di- 
aminedichloroplatinum; VPL, verapamil 
c SR, sensitization ratio. The DNR concentration that causes 50% 
growth inhibition (ICs0) in the MTT assay divided by the DNR concen- 
tration in the presence of 6.6 pM verapamil that reaches the ICs0 
a The percentage intracelhilar fluorescent DNR determined in an accu- 
mulation assay by flow cytometry. The fluorescence of DNR in the 
parental line is defined as 100% 
e ND, not done 
f P glycoprotein expression i  cells was determined by flow cytometry 
with the monoclonal antibody C-219. The immunofluorescence staining 
is indicated with +++ for bright staining, ++ for clear, + for moderate, 
+ for feeble, and - for no staining 
(resistance tocolchicin 0.6 x,  to daunorubicin 0.25 x ), but the resistance 
to cisplatin is maintained (4 x ) as in the CC531-COL line [13, 14]. See 
Table 1 for characteristics. 
YAC-1, a mouse T cell lymphoma, sensitive to NK cell lysis, was 
used as a positive control in the NK cell experiments. P815, a mouse 
mastocytoma, NK-cell-lysis-resistant but sensitive to LAK cell lysis, was 
used as a negative control in NK cell experiments and as a positive 
control in aLAK cell cytotoxicity tests. Both cell lines were grown in 
suspension i RPMI-1640 medium, (Dutch modification; Gibco) supple- 
mented with 10% FCS, 2 mM glutamine, 100 IU/ml penicillin and 100 
gg/ml streptomycin. 
Cell lines were grown in drug-free medium for at least 72 h before 
being used in tests. Adherent growing cells were isolated by trypsiniza- 
tion. Viability, determined by trypan blue exclusion, was more than 90% 
in all experiments (85% for YAC-1 and P815 cells). Regular screening 
for Mycoplasma infection was performed. 
The NK and aLAK cell experiments were conducted in complete 
RPMI medium (10% FCS) without HEPES buffer. Complete LAK me- 
dium for the generation of aLAK cells consisted of complete RPMI 
medium plus 1000 EuroCetus units IL-2/ml and 50 glVI 2-mercap- 
toethanol. 
Chemicals. 2-Mercaptoethanol was obta!ned from J.T. Baker, Deventer, 
The Netherlands; interleukin-2 (IL-2) from EuroCetus, Amsterdam, The 
Netherlands; 1% sodium dodecyl sulfate from Merck, Darmstadt, Ger- 
many; sodium [51Cr]chromate from Amersham, Aylesbury, UK. 
Preparation ofeffector cells. Spleens were removed aseptically from the 
rats and crushed with the hub of a syringe in complete medium. Spleen 
cells were incubated for 5 rain at 37~ in a buffered ammonium chloride 
solution to lyse the erythrocytes. For the NK cytotoxicity tests ceils were 
rested for 1 h in complete medium at 37~ in 25-cm 2 culture flasks 
(Costar, Cambridge, Mass.) to remove the macrophages byadherence to
the plastic. The remaining free-floating cells were aspirated, counted, and 
added to 96-well round-bottomed microtiter plates (Costar). In the NK 
cell lysis tests effector:target (E:T) cell ratios were 200:1,100:1, 50:1 and 
25:1. 
For the aLAK cell cytotoxicity tests cells were passed over nylon- 
wool columns to remove monocytes/macrophages and B cells [17]. 
Samples containing 2 x 108 spleen cells were added to a syringe contain- 
ing 0.6 g sterile nylon wool (Cellular Products, Buffalo, N.Y.) and 
incubated for 1 h at 37~ The nonadherent cells were carefully washed 
out with 50 ml medium. These cells were cultured at a concentration f 
2 x 106 cells in 75-cm 2culture flasks in LAK medium for 24 h. Then only 
the cells adherent to the plastic of the flasks were cultured further in 
conditioned medium to make the aLAK cell bulk culture. Conditioned 
medium was prepared by decanting the medium from the flasks, remov- 
ing the uonadherent ceils by centrifugation a d passing the supernatant 
through a0.45-gm Millipore filter [40]. After 72 h all cultured cells were 
collected; the adherent cells by adding EDTA and scraping the flask with 
a rubber policeman. In the aLAK cell lysis experiments E:T cell ratios 
were 50:1, 25:1, 12.5:1 and 6.25:1. 
Cytotoxicity assay. Sensitivity to NK and aLAK cells was tested in the 
51Cr-release cytotoxicity assay. Samples containing 1• 10 6 target cells 
were incubated for 1 h with 200 gCi 51Cr in 200 gl medium. Cells were 
washed three times with complete medium and counted, and 1 • 104 cells 
in 100 gl complete medium were added to the effector ceils (100 gl) in 
the plates. Spontaneous release was tested in wells containing target cells 
and medium (100 gl) only; maximal release was obtained by adding 100 
gl 1% sodium dodecyl sulfate to target cells. Tests were performed in 
triplicate and all tests were repeated at least wice. Plates were incubated 
for 4 h at 37~ The supernatant was harvested using the Skatron super- 
natant collection system (Skatron, Lier, Norway). The release of 51Cr 
was determined by counting radioactivity in a gamma counter (LBK 
Wallace Ultragamma II 1280, Wallace Instruments, Stockholm, Swe- 
den). The percentage specific cytotoxicity was calculated by the follow- 
ing formula: 
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Fig. 1. Natural killer (NK) cell lysis determined in a 4-h 51Cr-release 
assay. Mean specific lysis by NK cells of YAC- 1 (positive control), P815 
(negative control) and the cell lines CC531-PAR, CC531-REV, CC531- 
COL and CC531-CIS at E:T ratios of 25:1, 50:1, 100:1 and 200:1 is 
presented inthe graph. Error bars are standard errors of the mean 
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Fig. 2. Adherent lymphokine-activated killer (aLAK) cell lysis deter- 
mined after 4 h. Mean specific lysis (_+ SE) by aLAK cells of P815 
(positive control) and the cell lines CC531-PAR, CC531-REV, CC531- 
COL and CC531-CIS at E:T ratios of 6.25:1, 12.5:1, 25:1 and 50:1 is 
presented in the graph. Statistical significance at the 50:1 E:T ratio 
determined on the compilation of tests was found between CC531-CIS 
and CC531-COL (P = 0.019) 
-4- P815 ~- CC531-PAR -~- CC531 -REV 
CC531 -COL -z- CC531 -ClS 
Fig. 3. Adherent lymphokine-activated killer (aLAK) cell lysis deter- 
mined after 20 h. Mean specific lysis (• SE) by aLAK cells of P815 
(positive control) and the cell fines CC531-PAR, CC531-REV, CC531- 
COL and CC531-CIS at E:T ratios of 6.25:1, 12.5:1, 25:1 and 50:1 is 
presented inthe graph. Statistically significant differences at the 50:1 E:T 
ratio determined on the compilation of tests: CC53 I-CIS versus CC531- 
COL, P = 0.023; CC531-REV versus CC531-COL, P = 0.002; CC531- 
REV versus CC531-PAR, P = 0.02 
specific ytotoxicity (%) = 
[(experimental re ease - spontaneous release) 
100 x 
(total release - spontaneous release)]. 
Lytic units (LU) were calculated according to the method escribed 
by Pross et al. [28]. The calculations of lytic units and of statistical 
significance were done on the compilations ofdifferent tests. In figures, 
representative experiments are shown. 
Statistics. Statistical significance of the results was determined at the 
highest E:T ratios: 200:1 for NK cell lysis and 50:1 for aLAK cell lysis. 
The Student t-test (paired t-test) was used and a P value of less than 0.05 
was considered significant. 
Results 
NK cells of the WAG rat were h ighly effective against he 
NK-sens i t ive  YAC-1  cell l ine; up to 60% lysis was ob- 
served. The NK-res istant  cell  l ine P815 was not  lysed at 
all: less than 5% lysis was recorded at the 100:1 and 200:1 
E:T cell ratios. The CC531 cell l ines were rather resistant 
to NK cell lysis. At the highest (200:1) E:T cell ratio 
15%-22% specif ic lysis was found. See Fig. 1. There were 
no s igni f icant dif ferences in sensit iv ity between the CC531 
cell l ines. 
We used aLAK cells instead of LAK cells because the 
adherent cells were proven to be the most  effective cyto- 
toxic cells in bu lk  cultures with IL-2 [40]. A representat ive 
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Table 2. Activity of natural killer (NK) and adherent lymphokine-acti- 
vated killer (aLAK) cells 
Cell line Activity (LU/106 cells) a
NK aLAK 4 h aLAK 20 h 
YAC-1 5.5 
P815 0 10.4 21.7 
CC531 -PAR 0 0 10.1 
CC531-REV 0.6 3.2 13.9 
CC531-COL 0.3 0 7.1 
CC531-CIS 1.5 6.0 14.4 
a Lytic units/106 effector cells based on 15% lysis 
experiment for lysis by aLAK cells in a standard 4-h 51Cr- 
release assay is shown in Fig. 2. Maximal ysis of P815 was 
more than 60%, while lysis of the CC531 cell lines did not 
exceed 20%. At the maximal E:T ratio of 50:1 only minor 
differences in lysis were observed between some cell lines. 
CC531-CIS was significantly more sensitive to aLAK lysis 
compared to the least lysable cell line CC531-COL. 
As there were indications that the resistance to lysis by 
cytotoxic ells could be overcome by prolonging the in- 
cubation period, we extended the aLAK tests to 20 h. In 
these prolonged tests P815 cells appeared to be fragile as 
the spontaneous release was more than 25%. Specific lysis 
of P815 by aLAK cells was not enhanced by longer expo- 
sure to the cytotoxic ells in comparison with 4 h exposure. 
In all CC531 cell lines spontaneous release after 20 h was 
about 20%; CC531-PAR: 19.7 + 2.6% (SD), CC531- 
COL: 19.8 + 3.7%, CC531-REV: 20.1 ___ 7.3%, and 
CC531-CIS: 20.6 + 6.0%. In this prolonged assay none of 
the CC531 cell lines proved resistant to lysis by aLAK 
cells; specific lysis was more than 25% in all cell lines. 
Differences in sensitivity between the sublines became 
clearer (Fig. 3). In the compilation of tests CC531-COL 
appeared the most resistant line and, at the 50:1 E:T ratio, 
less than 30% lysis was found. CC531-REV and CC531- 
CIS proved to be the most lysable with more than 50% 
lysis after 20 h. The differences between CC531-REV and 
CC531-COL, and CC531-CIS and CC531-COL were sig- 
nificant. The same significant difference was found for 
CC531-REV compared to CC531-PAR, while CC531-CIS 
was found significantly more sensitive to aLAK lysis than 
the parental line in three out of four tests, but not in the 
compilation of four tests. Lyric units as values of cytotox- 
icity show the same order of sensitivity to aLAK cell 
mediated lysis in the 20-h assay, but differences between 
the cell lines are small. See Table 2. 
Discussion 
CC531 cells appeared to be rather resistant to tysis by 
cytotoxic ells. NK cell lysis was below 22% in all cell 
lines even at an E:T ratio of 200:1. No differences in 
specific lysis were observed between the CC531 cell lines. 
Lysis by IL-2-induced cytotoxic cells, aLAK cells, still 
was very low at a 50:1 E:T ratio, but some difference 
between the cell lines became apparent. We studied these 
differences in a prolonged assay. None of the cell lines was 
found to be completely resistant to aLAK lysis. The most 
drug-sensitive cell line, CC531-REV, with the least ex- 
pression of Pgp was the most sensitive to aLAK lysis, 
while the most drug resistant cell line, CC531-COL, 
seemed the most resistant to aLAK lysis. 
So far conflicting results have been reported about a 
possible correlation between drug resistance and sensitiv- 
ity to NK cell lysis. Various reports about doxorubicin-in- 
duced drug resistance showed enhanced resistance to NK- 
cell-mediated lysis in doxorubicin-resistant sublines [3, 6, 
41, 43]. In MDR cell lines, both no change in sensitivity [1, 
5, 16, 35] and also enhanced sensitivity to NK cell lysis 
compared to the parental cell lines [34] has been described. 
In contrast, Woods et al. reported iminished NK sensitiv- 
ity of an MDR subline with enhancement of sensitivity in a 
revertant cell line [42]. Treichel et al. only found this 
relationship for MDR cell lines that express Pgp, and not 
for non-Pgp MDR cell lines [37]. 
With regard to LAK cell sensitivity, various studies 
show no difference in lysability between drug-resistant cell 
lines and their parental ines [1, 3, 4, 12, 16, 25, 35]. 
Enhanced sensitivity as well as enhanced resistance of 
MDR cell lines to LAK cell lysis has been reported by 
others [10, 11, 12, 18, 30, 37]. An inverse relationship has 
also been found: the induction of LAK resistance in mela- 
noma cell lines rendered these more sensitive to doxorubi- 
cin [29]. Kimmig et al. found that LAK resistance corre- 
lated with the level of Pgp expression. A revertant cell line 
that was as drug sensitive as the parental line was found to 
be as lysable by LAK cells as the parental ceil line [18]. We 
did a comparable observation with the CC531 cell lines in 
the prolonged aLAK lysis assay. 
Explanations for the phenomenon fdifferences in sen- 
sitivity to cytotoxic ells between drug-sensitive and drug- 
resistant cells have been sought in differences in the ex- 
pression of cell membrane molecules. In most studies no 
correlation between MDR expression, NK or LAK cell 
resistance and expression of MHC class I and II antigens 
was observed [10, 31, 35]. With regard to adhesion 
molecules a correlation between enhanced LAK cell lysis 
and ICAM-1 and LFA-3 expression i  MDR cell lines was 
described [31], but other authors could not confirm these 
results using other cell lines [35]. 
To our knowledge only few reports about the associa- 
tion between cisplatin resistance and NK/LAK cell resis- 
tance have been published. In most experiments no influ- 
ence of cisplatin resistance on sensitivity to LAK-cell-me- 
diated lysis was observed [4, 16, 25, 29]. In one of their 
cisplatin-resistant cell lines Ohtsu et al. found enhanced 
sensitivity to LAK cell lysis [25]. Allevana et al. reported 
significant lysis by LAK cells of freshly isolated tumor 
cells from ovarian cancer patients that were refractory to 
chemotherapy with cisplatin [4]. In a recent article short- 
term pretreatment of cancer cells with cisplatin was re- 
ported to render these cells more sensitive to cytotoxic 
cells [24]. We observed enhanced lysis by aLAK cells of 
the cisplatin-resistant cell line CC531-CIS. In CC531-COL 
and CC531-REV cells a moderate resistance to cisplatin 
was found, about half the resistance of CC531-CIS. In 
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these two cell lines an association between their MDR 
phenotype and LAK resistance can be supposed, while the 
resistance to cisplatin seems of no importance. It is very 
possible that he colchicin induced MDR cell line CC531- 
COL and its revertant CC531-REV have a different mech- 
anism of cisplatin resistance from CC531-CIS, as this re- 
sistance was induced ifferently. 
It is clear from our results and those of others that basic 
research as not yet provided coherent data on the relation- 
ship between drug resistance and sensitivity to im- 
munotherapy. The lack of coherence in the results may be 
inherent o the different cell lines and the diversity of 
methods used to induce resistance. Possibly this reflects 
the heterogeneity of sensitivity and resistance todrugs and 
immunotherapy in the clinical situation. Our results eem 
to indicate that drug resistance does not preclude the use of 
immunotherapy with IL-2 and LAK cells, but enhancement 
of the efficacy of immunotherapy is necessary. With regard 
to Pgp-expressing multidrug-resistant tumors, an attractive 
approach might be to turn the strength of MDR cells into 
their weakness. This can be done by using antibodies 
against the multidrug transporter Pgp. Immunotoxin ther- 
apy using the anti-Pgp antibody MRK16 coupled to Pseu- 
domonas exotoxin has been shown to be effective against 
MDR cells in vitro and in vivo [9, 22, 23]. Another possible 
method of targeted immunotherapy is the use of bispecific 
monoclonal ntibodies directed against Pgp on one hand 
and against an antigen on cytotoxic ells on the other 
[7, 39]. Further esearch in this direction is warranted. 
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